Delivery Order SPE2DB20D3104-SPE2DB25FW0A5
Award Date 9/8/25
Potential Completion Date 9/9/25
Potential Value $7K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency awarded a $3,579.06 delivery order to AmerisourceBergen Drug Corp for Zepbound 5 mg/0.5 mL pen injectors on September 2, 2025, with completion targeted for September 3, 2025. This firm fixed-price delivery order represents a non-set-aside competitive award and is performed at the contractor's Conshohocken, Pennsylvania location. Zepbound is a semaglutide-based medication indicated for weight management, and this procurement supports federal medical supply...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Zepbound 12.5 mg/0.5 ml pen injections, valued at $6,035.72. This is a firm fixed-price delivery order with no set-aside designation, reflecting a competitively awarded contract. The order is scheduled for completion by August 14, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Zepbound is a GLP-1 receptor agonist...
- The Defense Logistics Agency awarded a $13,994.32 firm fixed price delivery order to AmerisourceBergen Drug Corp for Zepbound (semaglutide) 7.5 mg/0.5 mL pen injections on August 25, 2025, with ultimate completion by August 26, 2025. This non-set-aside competitive award represents a single delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The place of performance...
- The Defense Logistics Agency awarded a delivery order valued at $4,068.68 to AmerisourceBergen Drug Corp for the supply of Zepbound 7.5 mg/0.5 mL pen injectors on July 28, 2025, with completion scheduled for July 29, 2025. This firm fixed-price delivery order was competitively awarded without set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Zepbound is a semaglutide-based injectable medication used for weight...
- The Defense Logistics Agency awarded a Delivery Order valued at $10,288.27 to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Zepbound 10 mg/0.5 mL pen injectors. This competitively awarded contract, utilizing firm fixed pricing with no set-aside designation, calls for delivery by August 8, 2025, to the contractor's facility in Conshohocken, Pennsylvania. Zepbound is a GLP-1 receptor agonist medication commonly prescribed for weight management and metabolic health support....
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Zepbound 2.5 mg/0.5 mL pen injectors in 0.5 mL quantities, with a contract ceiling value of $32,050.85. This is a firm fixed-price delivery order with no set-aside designation, indicating the award was made through competitive procurement. The order will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, and...
- The Defense Logistics Agency awarded a delivery order valued at $28,363.85 to AmerisourceBergen Drug Corp for the supply of Zepbound 5 mg/0.5 ml pen injectors on August 15, 2025, with an ultimate completion date of August 18, 2025. This competitively awarded, firm fixed-price contract involves no set-aside designation and is being performed at the vendor's corporate office location in Conshohocken, Pennsylvania. Zepbound, a GLP-1 receptor agonist medication used for weight management, represents...
- The Defense Logistics Agency awarded a $2,594.37 firm fixed price delivery order to AmerisourceBergen Drug Corp on September 4, 2025, for the supply of Zepbound 7.5 mg/0.5 mL pens with an ultimate completion date of September 5, 2025. Zepbound is a semaglutide-based medication indicated for weight management and diabetes treatment. This non-set-aside award was competitively procured and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery...
- The Defense Logistics Agency awarded a delivery order valued at $2,971.10 to AmerisourceBergen Drug Corp for the supply of Zepbound 7.5 mg/0.5 mL pen injectors on August 8, 2025, with an ultimate completion date of August 11, 2025. This non-competitive, firm fixed-price delivery order was issued without a set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. Zepbound is a GLP-1 receptor agonist medication used for weight management...
- The Defense Logistics Agency awarded a $2,287.74 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Zepbound 10 mg/0.5 ml pen injection on July 30, 2025, with an ultimate completion date of July 31, 2025. This non-competitive delivery order represents a single-line item pharmaceutical procurement fulfilled from AmerisourceBergen's existing contract vehicle. The product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania. Zepbound is a...